Keytruda, first approved in 2014, belongs to a class of immunotherapy drugs that enable the immune system to attack cancer cells, extending survival for millions and transforming fatal diagnoses into manageable conditions.
Lilly's fourth quarter revenue reached $19.29 billion, up 42.6% year-over-year, powered almost entirely by two products. Mounjaro generated $7.41 billion, up 110%, while Zepbound added $4.26 billion, up 123%.